187218-03-7

Basic information

• Product Name: (R)-2-TETRAHYDROISOQUINOLINE ACETIC ACID HYDROCHLORIDE
• Synonyms: (R)-2-TETRAHYDROISOQUINOLINE ACETIC ACID HCL;(R)-2-TETRAHYDROISOQUINOLINE ACETIC ACID HYDROCHLORIDE;H-D-TQA-OH HCL;H-D-TIC-(C*CH2)OH HCL;(R)-2-tetrahydroisoquinolineaceticacidCl;(R)-1,2,3,4-Tetrahydro-3-isoquinolineacetic acid hydrochloride;(R)-2-Tetrahydroisoquinoline acetic acid
• CAS NO: 187218-03-7
• Molecular Formula: C11H14ClNO2
• Molecular Weight: 227.69
• Product Categories: 3-Amino-4-phenylbutanoic Acid Analogs;B-Amino
• Mol File: 187218-03-7.mol

Chemical Properties

• Boiling Point: 412.4 °C at 760 mmHg
• Flash Point: 203.2 °C
• Appearance: /
• Vapor Pressure: 1.54E-07mmHg at 25°C
• CAS DataBase Reference: (R)-2-TETRAHYDROISOQUINOLINE ACETIC ACID HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2-TETRAHYDROISOQUINOLINE ACETIC ACID HYDROCHLORIDE(187218-03-7)
• EPA Substance Registry System: (R)-2-TETRAHYDROISOQUINOLINE ACETIC ACID HYDROCHLORIDE(187218-03-7)

Safety Data

• Hazardous Substances Data: 187218-03-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(R)-2-TETRAHYDROISOQUINOLINE ACETIC ACID HYDROCHLORIDE is used as a pharmaceutical intermediate for its pivotal role in the synthesis of various drugs, contributing to the development of new medicinal compounds.
Used in Neuroprotective Therapy:
In the field of neuroprotection, (R)-2-TETRAHYDROISOQUINOLINE ACETIC ACID HYDROCHLORIDE is utilized for its potential to safeguard neurons from damage or degeneration, offering a promising avenue for the treatment of neurodegenerative diseases.
Used in Anti-Inflammatory Applications:
(R)-2-TETRAHYDROISOQUINOLINE ACETIC ACID HYDROCHLORIDE is employed as an anti-inflammatory agent, leveraging its properties to reduce inflammation, which is beneficial in the management of conditions characterized by excessive immune responses.
Used in Neurological and Psychiatric Disorders Treatment:
(R)-2-TETRAHYDROISOQUINOLINE ACETIC ACID HYDROCHLORIDE is used in the treatment of neurological and psychiatric disorders due to its ability to modulate neurotransmitter systems in the brain, potentially leading to improved therapeutic outcomes for patients suffering from such conditions.

InChI:InChI=1/C11H13NO2.ClH/c13-11(14)6-10-5-8-3-1-2-4-9(8)7-12-10;/h1-4,10,12H,5-7H2,(H,13,14);1H/t10-;/m1./s1

Upstream product

• 50-00-0 formaldehyd 
• 138165-77-2 (S)-3-amino-4-phenylbutanoic acid hydrochloride 

Relevant articles and documents

1-BENZYLSPIRO[PIPERIDINE-4,1′-PYRIDO[3,4-b]indole] ‘co-potentiators’ for minimal function CFTR mutants

We previously identified a spiro [piperidine-4,1-pyrido [3,4-b]indole] class of co-potentiators that function in synergy with existing CFTR potentiators such as VX-770 or GLGP1837 to restore channel activity of a defined subset of minimal function cystic fibrosis transmembrane conductance regulator (CFTR) mutants. Here, structure-activity studies were conducted to improve their potency over the previously identified compound, 20 (originally termed CP-A01). Targeted synthesis of 37 spiro [piperidine-4,1-pyrido [3,4-b]indoles] was generally accomplished using versatile two or three step reaction protocols with each step having high efficiency. Structure-activity relationship studies established that analog 2i, with 6′-methoxyindole and 2,4,5-trifluorobenzyl substituents, had the greatest potency for activation of N1303K-CFTR, with EC50 ～600 nM representing an ～17-fold improvement over the original compound identified in a small molecule screen.